New drug teclistamab tested in patients with Hard-to-Treat myeloma
NCT ID NCT06062537
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 200 adults with multiple myeloma whose cancer has returned or stopped responding to treatment. They are receiving teclistamab, a drug that helps the immune system find and destroy myeloma cells. Researchers are measuring how many patients respond to the drug and monitoring side effects in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teclistamab (a drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this study could confirm that teclistamab works well and is safe for patients with multiple myeloma who have not responded to other treatments.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Teclistamab can cause serious side effects like infections or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Bretagne Atlantique
Vannes, France
-
CH Dunkerque
Dunkirk, France
-
CH Perpignan
Perpignan, France
-
CH d'ANNECY
Annecy, France
-
CH de METZ
Metz, France
-
CHU Amiens Picardie
Amiens, France
-
CHU Bordeaux
Bordeaux, 31400, France
-
CHU CAEN
Caen, France
-
CHU Clermont-Ferrand Site Estaing
Clermont-Ferrand, France
-
CHU Henri Mondor
Créteil, France
-
CHU Saint-Eloi - CHU de Montpellier
Montpellier, France
-
CHU Toulouse
Toulouse, France
-
CHU de Besançon
Besançon, France
-
CHU de Lille
Lille, France
-
CHU de Nice
Nice, France
-
CHU de Tours
Tours, France
-
Centre Henri Becquerel
Rouen, France
-
Centre hospitalier Métropole de Savoie
Chambéry, France
-
Centre hospitalier d'Argenteuil
Argenteuil, France
-
Centre hospitalier de Brive-la-Gaillarde
Brive-la-Gaillarde, France
-
Chu Dijon
Dijon, France
-
Chu de Nantes
Nantes, France
-
Chu de Rennes
Rennes, France
-
Groupe hospitalier Bretagne Sud
Lorient, France
-
Hopital Necker
Paris, France
-
Hopital Novo
Pontoise, France
-
Hopital de Hautepierre
Strasbourg, France
-
Hopital de la cote Basque
Bayonne, France
-
Hopital saint louis
Paris, France
-
Institut Paoli Calmette
Marseille, France
-
Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne
Saint-Priest-en-Jarez, France